Akums Drugs and Pharmaceuticals Ltd

Net profit of Akums Drugs & Pharmaceuticals declined 37.46% to Rs 40.78 crore in the quarter ended September 2025 as against Rs 65.21 crore during the previous quarter ended September 2024. Sales declined 1.51% to Rs 1017.53 crore in the quarter ended September 2025 as against Rs 1033.09 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales1017.531033.09 -2 OPM %9.2811.73 - PBDT103.54122.75 -16 PBT65.6787.89 -25 NP40.7865.21 -37 Powered by Capital Market - Live

Akums Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 November 2025.Powered by Capital Market - Live

Securities in F&O Ban: RBL Bank, PG Electroplast and Titagarh Rail Systems shares are banned from F&O trading on 25 August 2025. Stocks to Watch: GMR Power and Urban Infra said that its board has approved a fundraising proposal upto Rs 3,000 crore via multiple instruments. The company will issue fully paid-up equity shares, non-convertible debentures along with warrants and/or convertible securities other than warrants and/or any other securities either through qualified institutions placement (QIP) or any other method and/or issue of foreign currency convertible bonds. Oswal Greentech announced that it has acquired 4.99% stake in Oswal Agro Mills (OAML) for a total consideration of Rs 50.91 crore. Oswal Greentech is a promoter of OAML, has acquired 66,99,000 shares of OAML with nominal value of Rs 10 each. Akums Drugs & Pharmaceuticals has executed a framework agreement with Government of the Republic of Zambia (GRZ) to establish a local manufacturing facility and supply medicines in Zambia. This project shall be implemented through incorporation of a new joint venture company in Zambia in which Akums will be a majority partner owning 51% stake and a nominated Zambian state instrumentality owning 49% stake. Brigade Enterprises said that it has entered into a long-term lease agreement for a prime site of about 7-acres located on Old Mahabalipuram Road (OMR), one of Chennai's most dynamic commercial corridors. The site will be developed into a landmark mixed-use destination that will feature a Grade-A office space of over 1 million square feet and a 5-Star deluxe hotel of about 225 keys. InterGlobe Aviation (Indigo) and Max Healthcare to become part of Nifty 50 index. They will replace Hero MotoCorp & IndusInd Bank in the 50-share benchmark Nifty 50 index, effective 30 September 2025. JNK India has received a significant order from its promoter entity, JNK Global Co., Korea, to provide design and engineering support for the cracker furnace package of a refinery project in India. The order pertains to support services for JNK Global's refinery project and will be executed in India. The order is classified as significant by the company, indicating a contract value in the range of Rs 0'50 crore. The scheduled delivery date for the project is 21 December 2027. Ashapuri Gold Ornament has secured an order worth Rs 5.41 crore from renowned national retail jewellery chains for the supply of gold jewellery of Aneya Brand (Polki and Diamond) Collection. The company stated that the order is to be executed within 45 days. Interarch Building Solutions has received an order worth approximately Rs 90 crore from Rungta Mines for the design, engineering, manufacturing, supply, and erection of a pre-engineered steel building system. The project will be executed over a period of 6 to 8 months. Payment terms include a 10% advance and an additional 10% upon approval of drawings and designs.Powered by Capital Market - Live

The company will establish the facility with the objective of supporting GRZ national health programs and enhancing local production capabilities in Zambia. The facility, in the future, also plans to export to neighboring countries including, but not limited to, Zimbabwe, Namibia, Botswana, Malawi, Tanzania, Mozambique etc. This project shall be implemented through incorporation of a new joint venture company in Zambia in which Akums will be a majority partner owning 51% stake and a nominated Zambian state instrumentality owning 49% stake. The facility is expected to commence manufacturing in 2028. The facility plans to manufacture general oral solids, liquids, injectables as well as beta-lactam products. Both the JV partners will jointly invest in the facility and commercial operations in ratio of their respective shareholding. Further, until such time as the manufacturing facility will be established and becomes operational, the GRZ, through its state instrumentality, shall purchase medicines from the joint venture company having a minimum aggregate value of $ 50 million over 2 years in 2026 and 2027, i.e. $25 million annually, which will be manufactured and supplied from Akums and/or its subsidiaries' facilities in India. The JV is expected to be established before the year end 2025. In furtherance of this collaboration, the company has agreed to provide its proprietary technology, know-how, and technical expertise to the JV, and the parties intend to enter into a separate technology transfer agreement. Akums Drugs and Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. The company's consolidated net profit increased 5.5% to Rs 63.48 crore in Q1 FY26, compared with Rs 60.17 crore in Q1 FY25. Net sales inched up 0.5% YoY to Rs 1024.03 crore in Q1 FY26. The scrip shed 0.15% to end at Rs 480.55 on the BSE.Powered by Capital Market - Live

Net profit of Akums Drugs & Pharmaceuticals rose 5.50% to Rs 63.48 crore in the quarter ended June 2025 as against Rs 60.17 crore during the previous quarter ended June 2024. Sales rose 0.48% to Rs 1024.03 crore in the quarter ended June 2025 as against Rs 1019.11 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales1024.031019.11 0 OPM %12.5912.56 - PBDT132.57121.54 9 PBT95.6587.48 9 NP63.4860.17 6 Powered by Capital Market - Live

Akums Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 8 August 2025.Powered by Capital Market - Live

Akums Drugs & Pharmaceuticals announced that the 21st Annual General Meeting(AGM) of the company will be held on 18 July 2025.Powered by Capital Market - Live

Net profit of Akums Drugs & Pharmaceuticals reported to Rs 147.62 crore in the quarter ended March 2025 as against net loss of Rs 41.32 crore during the previous quarter ended March 2024. Sales rose 11.79% to Rs 1055.55 crore in the quarter ended March 2025 as against Rs 944.21 crore during the previous quarter ended March 2024. For the full year,net profit reported to Rs 338.18 crore in the year ended March 2025 as against net loss of Rs 4.04 crore during the previous year ended March 2024. Sales declined 1.44% to Rs 4118.16 crore in the year ended March 2025 as against Rs 4178.18 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales1055.55944.21 12 4118.164178.18 -1 OPM %8.900.32 -11.282.94 - PBDT106.910.85 12478 482.00106.39 353 PBT66.92-33.10 LP 328.55-19.25 LP NP147.62-41.32 LP 338.18-4.04 LP Powered by Capital Market - Live

Akums Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 26 May 2025.Powered by Capital Market - Live

Net profit of Akums Drugs & Pharmaceuticals declined 66.35% to Rs 65.18 crore in the quarter ended December 2024 as against Rs 193.70 crore during the previous quarter ended December 2023. Sales declined 6.69% to Rs 1010.41 crore in the quarter ended December 2024 as against Rs 1082.84 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales1010.411082.84 -7 OPM %12.018.63 - PBDT130.7989.91 45 PBT86.2758.36 48 NP65.18193.70 -66 Powered by Capital Market - Live